Rezolute, Inc. reported for the three months ended March 31, 2026 results: net income $16.2 million.
“Net loss was $16.2 million for the third quarter of fiscal 2026 compared with a net loss of $18.9 million for the same period a year ago.”
Rezolute, Inc. — fact timeline
Source-grounded facts extracted from Rezolute, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Erik Harris was elected as Director at Rezolute, Inc..
“On March 25, 2025, the Board of Directors (the “Board”) of Rezolute, Inc. (the “Company”) upon the recommendation of the Company’s nominating and corporate governance committee elected Erik Harris to the Board, effective March 25, 2025”
Rezolute, Inc.: Increased authorized common stock from 100,000,000 shares to 165,000,000 shares (effective 2024-12-06).
“The Certificate of Amendment increases the Company’s authorized common stock from 100,000,000 shares to an aggregate of 165,000,000 shares.”
Rezolute, Inc. shareholders approved Equity Plan Amendment Proposal at the 2024-05-16 meeting.
“Proposal No. 4 - Equity Plan Amendment Proposal To approve an amendment to the Company’s 2021 Stock Incentive Plan to reflect the adoption of the Company’s incentive compensation recovery policy: Votes For Votes Against Abstentions Broker Non Votes 26,551,450.000 338,688 172,517 431,722”
Rezolute, Inc. shareholders approved Say-on-Pay Proposal at the 2024-05-16 meeting.
“Proposal No. 3 - Say-on-Pay Proposal To approve by a non-binding advisory vote, the compensation of the Company’s named executive officers, as disclosed in the Executive Compensation section of the proxy statement: Votes For Votes Against Abstentions Broker Non Votes 26,684,240 225,756 152,659 431,722”
Rezolute, Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2024-05-16 meeting.
“Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm To ratify Grant Thornton LLP as the Company’s independent registered public accounting firm for fiscal year 2024: Votes For Votes Against Abstentions Broker Non Votes 27,350,525 3,686 140,166 431,722”
Rezolute, Inc. shareholders approved Election of Directors at the 2024-05-16 meeting.
“Proposal No. 1 - Election of Directors To elect the following nominees to serve as members of the Company’s board of directors: Nominee Name Votes For Votes Withheld Broker Non Votes Young-Jin Kim 26,867,423 195,232 431,722 Nevan Charles Elam 27,027,137 35,518 431,722 Philippe Fauchet 26,839,313 223,342 431,722 Gil Labrucherie 26,909,378 153,277 431,722 Wladimir Hogenhuis 26,839,313 223,342 431,722 Nerissa Kreher 26,839,040 223,615 431,722”
Rezolute, Inc. reported the three months ended March 31, 2024 results: net income $17.1 million.
“Net loss was $17.1 million for the third quarter of fiscal 2024 compared with a net loss of $15.7 million for the same period a year ago.”
Rezolute, Inc. entered into Exchange Agreement with certain Company stockholders valued at aggregate of 3,000,000 shares of common stock (effective 2024-03-08).
“On March 8, 2024, Rezolute, Inc. (the “Company”) entered into a securities exchange agreement (the “Exchange Agreement”) with certain Company stockholders (the “Exchanging Stockholders”), pursuant to which the Company exchanged an aggregate of 3,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Retired Shares”), owned by the Exchanging Stockholders for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 3,000,000 shares of common stock”
Rezolute, Inc. engaged Grant Thornton LLP as its auditor.
“On March 8, 2024, the Company appointed Grant Thornton LLP (“Grant Thornton”) as its new independent registered public account firm.”
Rezolute, Inc. dismissed Plante & Moran, PLLC as its auditor.
“On March 8, 2024, the Company dismissed Plante & Moran, PLLC (“Plante Moran”) as its independent registered public accounting firm.”
Rezolute, Inc. reported second quarter of fiscal 2024 ended December 31, 2023 results: net income $13.9 million.
“Net loss was $13.9 million for the second quarter of fiscal 2024, compared to $13.6 million for the same period in fiscal 2023”
Daron Evans was appointed as Chief Financial Officer at Rezolute, Inc..
“On January 23, 2024, the Company’s Board of Directors approved the appointment of Mr. Evans, 50 years of age, to serve as the Company’s Chief Financial Officer.”
Rezolute, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“November 21, 2023, Rezolute, Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of Nasdaq Stock Market (“ Nasdaq ”) indicating that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive trading days, the Company was no longer in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “ Bid Price Requirement ”). The Notice has no immediate effect on the listing of the Company’s co”
Rezolute, Inc. reported financial results for the fourth quarter and full fiscal year ended June 30, 2023.
“On September 14, 2023, Rezolute, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2023.”
Rezolute, Inc.: Amended and restated Code of Business Conduct and Ethics to improve readability and clarify policies on compliance, conflicts of interest, insider trading, and related matters, superseding the prior code without any waiver (effective 2023-05-30).
“On May 30, 2023, the Rezolute, Inc. (the “Company”) Board of Directors (the “Board”) approved an Amended and Restated Code of Business Conduct and Ethics in its entirety (the “Code”).”
Rezolute, Inc. shareholders approved Approve, by a non-binding advisory vote, the preferred frequency of one year for future advisory votes on the compensation of the Company's named executive officers at the 2023-05-25 meeting.
“Proposal No. 4 - Say-on-Frequency Proposal To approve, by a non-binding advisory vote, the preferred frequency of one year for future advisory votes on the compensation of the Company's named executive officers: 3 Years 2 Years 1 Year Abstain Broker Non Votes 1,378,333 495,535 25,947,811 177,521 58,061”
Rezolute, Inc. shareholders approved Approve by a non-binding advisory vote, the compensation of the Company's named executive officers, as disclosed in the Executive Compensation section of the proxy statement at the 2023-05-25 meeting.
“Proposal No. 3 - Say-on-Pay Proposal To approve by a non-binding advisory vote, the compensation of the Company's named executive officers, as disclosed in the Executive Compensation section of the proxy statement: Votes For Votes Against Abstentions Broker Non Votes 27,799,551 199,289 360 58,061”
Rezolute, Inc. shareholders approved Ratify Plante & Moran, PLLC as the Company's independent registered public accounting firm for fiscal year ending June 30, 2023 at the 2023-05-25 meeting.
“Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm To ratify Plante & Moran, PLLC as the Company's independent registered public accounting firm for fiscal year ending June 30, 2023: Votes For Votes Against Abstentions Broker Non Votes 28,057,059 202 0 0”
Rezolute, Inc. reported third quarter of fiscal 2023 ended March 31, 2023 results: net income $15.7 million.
“Net loss was $15.7 million for the third quarter of fiscal 2023, compared to $11.2 million for the same period in fiscal 2022.”
Rezolute, Inc. reported financial results for second quarter of fiscal 2023 ended December 31, 2022.
“On February 10, 2023, Rezolute, Inc. issued a press release announcing its financial results for the second quarter ended December 31, 2022.”
Rezolute, Inc. reported the first quarter of fiscal 2023 ended September 30, 2022 results: net income Net loss was $9.8 million for the first quarter of fiscal 2023.
“Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced its financial results for the first quarter of fiscal 2023 ended September 30, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.